Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) EBITDA Margin: 2015-2025

Historic EBITDA Margin for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -7,945.13%.

  • Cartesian Therapeutics' EBITDA Margin fell 169242.00% to -7,945.13% in Q3 2025 from the same period last year, while for Sep 2025 it was -4,395.97%, marking a year-over-year decrease of 388527.00%. This contributed to the annual value of -199.02% for FY2024, which is 64605.00% up from last year.
  • Per Cartesian Therapeutics' latest filing, its EBITDA Margin stood at -7,945.13% for Q3 2025, which was down 248.93% from 5,334.90% recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' EBITDA Margin ranged from a high of 5,334.90% in Q2 2025 and a low of -7,945.13% during Q3 2025.
  • Over the past 3 years, Cartesian Therapeutics' median EBITDA Margin value was -365.01% (recorded in 2023), while the average stood at -1,174.38%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by 1,170,843bps in 2021, then skyrocketed by 529,349bps in 2025.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' EBITDA Margin stood at 40.86% in 2021, then crashed by 594bps to 34.92% in 2022, then crashed by 218,399bps to -2,149.07% in 2023, then spiked by 350,190bps to 1,352.83% in 2024, then slumped by 169,242bps to -7,945.13% in 2025.
  • Its EBITDA Margin was -7,945.13% in Q3 2025, compared to 5,334.90% in Q2 2025 and -1,607.09% in Q1 2025.